HAEMONETICS CORP's ticker is HAE and the CUSIP is 405024100. A total of 244 filers reported holding HAEMONETICS CORP in Q2 2022. The put-call ratio across all filers is 1.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $29,527,449 | +933.7% | 329,621 | +882.4% | 0.02% | +1400.0% |
| Q2 2023 | $2,856,617 | +267875.3% | 33,552 | +160.5% | 0.00% | 0.0% |
| Q1 2023 | $1,066 | -97.0% | 12,882 | -97.1% | 0.00% | -95.0% |
| Q4 2022 | $35,007 | -99.9% | 445,100 | -40.9% | 0.02% | -39.4% |
| Q3 2022 | $55,782,000 | +152.5% | 753,508 | +122.3% | 0.03% | +135.7% |
| Q2 2022 | $22,091,000 | +1571.0% | 338,926 | +1520.7% | 0.01% | +1300.0% |
| Q1 2022 | $1,322,000 | -88.0% | 20,912 | -90.0% | 0.00% | -83.3% |
| Q4 2021 | $11,051,000 | -80.6% | 208,349 | -74.2% | 0.01% | -82.4% |
| Q3 2021 | $56,984,000 | +20.7% | 807,252 | +14.0% | 0.03% | +21.4% |
| Q2 2021 | $47,206,000 | +7.9% | 708,384 | +79.8% | 0.03% | -9.7% |
| Q1 2021 | $43,744,000 | -0.6% | 394,059 | +6.4% | 0.03% | -3.1% |
| Q4 2020 | $43,989,000 | +70.6% | 370,425 | +25.4% | 0.03% | 0.0% |
| Q3 2020 | $25,782,000 | -4.7% | 295,496 | -2.1% | 0.03% | -13.5% |
| Q2 2020 | $27,041,000 | +911.6% | 301,940 | +1025.8% | 0.04% | +516.7% |
| Q1 2020 | $2,673,000 | -67.1% | 26,821 | -62.1% | 0.01% | -40.0% |
| Q4 2019 | $8,131,000 | -59.6% | 70,762 | -55.7% | 0.01% | -68.8% |
| Q3 2019 | $20,139,000 | +228.4% | 159,659 | +213.4% | 0.03% | +255.6% |
| Q2 2019 | $6,132,000 | +130.4% | 50,952 | +67.5% | 0.01% | +125.0% |
| Q1 2019 | $2,661,000 | -81.5% | 30,419 | -75.8% | 0.00% | -77.8% |
| Q3 2018 | $14,413,000 | -30.1% | 125,792 | -45.3% | 0.02% | -33.3% |
| Q2 2018 | $20,622,000 | -76.2% | 229,949 | -80.6% | 0.03% | -76.7% |
| Q1 2018 | $86,588,000 | +2250.4% | 1,183,544 | +1765.9% | 0.12% | +2220.0% |
| Q4 2017 | $3,684,000 | -73.2% | 63,429 | -79.3% | 0.01% | -76.2% |
| Q3 2017 | $13,767,000 | -7.0% | 306,824 | -18.2% | 0.02% | -19.2% |
| Q2 2017 | $14,807,000 | -37.1% | 374,948 | -35.4% | 0.03% | -39.5% |
| Q1 2017 | $23,555,000 | +36.0% | 580,610 | +34.8% | 0.04% | +19.4% |
| Q4 2016 | $17,321,000 | +506.3% | 430,871 | +446.1% | 0.04% | +620.0% |
| Q3 2016 | $2,857,000 | -78.2% | 78,906 | -82.5% | 0.01% | -83.3% |
| Q2 2016 | $13,102,000 | +90.7% | 451,963 | +130.2% | 0.03% | +76.5% |
| Q1 2016 | $6,869,000 | +111.5% | 196,356 | +94.9% | 0.02% | +142.9% |
| Q4 2015 | $3,247,000 | -59.2% | 100,725 | -59.1% | 0.01% | -53.3% |
| Q3 2015 | $7,966,000 | +2494.8% | 246,488 | +3221.9% | 0.02% | +1400.0% |
| Q2 2015 | $307,000 | -93.4% | 7,420 | -92.8% | 0.00% | -88.9% |
| Q1 2015 | $4,623,000 | +55.6% | 102,917 | +29.6% | 0.01% | +50.0% |
| Q4 2014 | $2,972,000 | -8.7% | 79,421 | -14.8% | 0.01% | -25.0% |
| Q3 2014 | $3,256,000 | -3.1% | 93,234 | -2.1% | 0.01% | -11.1% |
| Q2 2014 | $3,360,000 | -51.4% | 95,234 | -55.1% | 0.01% | -55.0% |
| Q1 2014 | $6,914,000 | +262.7% | 212,157 | +369.0% | 0.02% | +233.3% |
| Q4 2013 | $1,906,000 | -44.2% | 45,234 | -47.2% | 0.01% | -45.5% |
| Q3 2013 | $3,418,000 | -54.2% | 85,717 | -52.5% | 0.01% | -52.2% |
| Q2 2013 | $7,460,000 | – | 180,404 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Millrace Asset Group, Inc. | 19,264 | $1,726 | 2.13% |
| Parkman Healthcare Partners LLC | 88,962 | $7,969,216 | 1.46% |
| HEARTLAND ADVISORS INC | 256,414 | $24,435,274 | 1.37% |
| Riverwater Partners LLC | 15,553 | $1,393,238 | 1.27% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 111,100 | $9,952,338 | 1.15% |
| Lisanti Capital Growth, LLC | 78,425 | $7,025,312 | 1.11% |
| Aristotle Capital Boston, LLC | 311,666 | $27,919,054 | 0.90% |
| ROYCE & ASSOCIATES LP | 947,550 | $84,881,529 | 0.86% |
| CHASE INVESTMENT COUNSEL CORP | 18,770 | $1,681 | 0.84% |
| Virtus Investment Advisers, Inc. | 13,662 | $1,223,842 | 0.83% |